- Neuraxpharm, Europe’s leading CNS specialty company, announces expansion into the Nordics
- Establishes business unit in Stockholm and appoints Magnus Wassén as General Manager Neuraxpharm Nordics
Düsseldorf and Barcelona, April 7, 2021 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), is expanding its business into Northern Europe. The new business unit, based in Stockholm, will be led by Magnus Wassén, General Manager Neuraxpharm Nordics, and will leverage Neuraxpharm’s CNS expertise to offer suitable products from the company´s extensive portfolio in the Nordic markets.
Neuraxpharm Sweden will cover the country markets of Sweden, Norway, Finland, Denmark and Iceland. Through this expansion, Neuraxpharm strengthens its position as the leading CNS specialist in Europe and successively establishes the brand in further strong-selling markets. In Sweden, Norway and Finland combined, the CNS market is growing by an average of 8% 1, with Sweden alone representing the ninth largest CNS market in Europe 1 with a volume of over EUR 650 million 1.